Price List - Loargys - Metabolic Agents-Misc - Replacement E.xlsx
XLSX spreadsheet 47 KB Posted
- Solicitation number
- HT9402-26-Q-9203
- Issued by
-
Defense Health Agency
About this file
This is a price list template for the Department of War (DoW) Pharmacy Uniform Formulary Blanket Purchase Agreement (BPA) and Uniform Formulary Additional Discount Program (ADP) for metabolic agents in the replacement enzymes subclass, with quotes due April 27, 2026, for the May 6-7, 2026 P&T Committee meeting. The document provides templates for ten newly approved drugs (identified as Drug #1 through Drug #10) requiring manufacturers to submit pricing quotes for both Military Treatment Facility/Mail Order and TRICARE Retail scenarios. For the BPA section, manufacturers must provide price per NDC package size and price per unit for both Uniform Formulary and Non-Formulary categories. For the ADP section, manufacturers can submit pricing using either non-FAMP (non-Federal Acquisition Matching Program) discount methodology or WAC (Wholesale Acquisition Cost) discount methodology, with options for Tier 2 and Tier 3 cost-sharing categories and corresponding refund calculations based on Federal Ceiling Price or WAC pricing benchmarks.
Key administrative requirements include submission of the Quote Review Checklist and fully executed signature pages alongside pricing data. The formulary notes indicate that prior authorization may apply, agents will be reviewed at the quarterly P&T Committee meeting per 32 CFR 199.21(g)(5), and the P&T Committee may recommend preferential status (treated as Tier 1 generics for cost-sharing) or complete exclusion from the TRICARE pharmacy benefit program. All quoted prices per unit of measure must remain consistent across all available package sizes (30s, 100s, 1000s) within each dispensing venue. Non-FAMP discounts remain static throughout the agreement life, though calculated refunds may change annually based on updated Federal Ceiling Price benchmarks, while WAC discounts remain static with pricing adjusted quarterly based on daily weighted WAC changes.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price List - Arynta - ADHD Agents - Stimulants.xlsx | XLSX spreadsheet | |
| Price List - Desmoda - Endocrine Agents Misc - NA.xlsx | XLSX spreadsheet | |
| Price List - Foundayo - Metabolic Dysfunction A - Weight Loss A.xlsx | XLSX spreadsheet | |
| Price List - Kygevvi - Metabolic Agents Misc - NA.xlsx | XLSX spreadsheet | |
| Price List - Icotyde - TIBS -IL-23.xlsx | XLSX spreadsheet | |
| Price List - Lerochol - Antilipidemics-1 - PCSK-9.xlsx | XLSX spreadsheet | |
| Price List - Avtozma - TIBS - IL-1 IL-6 CTLA-4.xlsx | XLSX spreadsheet | |
| Price List - Yuviwel - Growth Stimulating Agents - NA.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf | ||
| RFQ HT9402-26-Q-9203.pdf | ||
| Price List - Atmeksi - Skeletal Muscle Relaxants and Comb - NA.xlsx | XLSX spreadsheet |
Show all 12
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the May 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263MAREG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263MAREG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #2 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263MAREG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263MAREG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263MAREG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263MAREG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263MAREG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263MAREG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263MAREG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263MAREG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263MAREG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263MAREG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263MAREG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263MAREG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263MAREG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263MAREG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263MAREG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263MAREG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263MAREG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263MAREG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Appendix for the May 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote | ||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote | ||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (WAC Discount)
| UF ADP Appendix for the May 2026 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DoW Uniform Formulary Class: | METABOLIC AGENTS - MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DoW Uniform Formulary Subclass: | REPLACEMENT ENZYMES | Quotes due: | April 27, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263MAREG1T21M | Tier 2 | 1 or more | |
| 263MAREG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .